Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics has told the ASX it is not aware of any undisclosed price-sensitive information that would explain a recent rise in its share price and trading volumes. The company confirmed it remains in full compliance with ASX continuous disclosure rules and that its board has approved the response.
Atomo noted that Lumos Diagnostics has entered a trading halt pending an update on the U.S. FDA response to a CLIA waiver application for the FebriDx test, which exclusively uses Atomo’s Pascal cassette. Atomo said it does not yet know the outcome or impact of the FDA process on its own business but will continue to engage with Lumos and update the market when more information becomes available.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian medical diagnostics company focused on rapid point-of-care testing solutions. Its patented Pascal cassette technology is used in third-party tests, including Lumos Diagnostics’ FebriDx, to enhance usability and reliability for end users in clinical and near-patient settings.
Average Trading Volume: 1,573,814
Technical Sentiment Signal: Buy
Current Market Cap: A$28.36M
For a thorough assessment of AT1 stock, go to TipRanks’ Stock Analysis page.